These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28455313)

  • 1. Transient transcription factor (OSKM) expression is key towards clinical translation of
    de Lázaro I; Cossu G; Kostarelos K
    EMBO Mol Med; 2017 Jun; 9(6):733-736. PubMed ID: 28455313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spermatogonial stem cells and progenitors are refractory to reprogramming to pluripotency by the transcription factors Oct3/4, c-Myc, Sox2 and Klf4.
    Corbineau S; Lassalle B; Givelet M; Souissi-Sarahoui I; Firlej V; Romeo PH; Allemand I; Riou L; Fouchet P
    Oncotarget; 2017 Feb; 8(6):10050-10063. PubMed ID: 28052023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs).
    Singh VK; Kumar N; Kalsan M; Saini A; Chandra R
    J Stem Cells; 2015; 10(1):43-62. PubMed ID: 26665937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Histone Variants TH2A and TH2B Enhance Human Induced Pluripotent Stem Cell Generation.
    Huynh LM; Shinagawa T; Ishii S
    Stem Cells Dev; 2016 Feb; 25(3):251-8. PubMed ID: 26649967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming of somatic cells to pluripotency.
    Nakagawa M; Yamanaka S
    Adv Exp Med Biol; 2010; 695():215-24. PubMed ID: 21222208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical roles of Cyclin D1 in mouse embryonic fibroblast cell reprogramming.
    Oh HR; Kim J; Kim J
    FEBS J; 2016 Dec; 283(24):4549-4568. PubMed ID: 27790870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo.
    Mosteiro L; Pantoja C; Alcazar N; Marión RM; Chondronasiou D; Rovira M; Fernandez-Marcos PJ; Muñoz-Martin M; Blanco-Aparicio C; Pastor J; Gómez-López G; De Martino A; Blasco MA; Abad M; Serrano M
    Science; 2016 Nov; 354(6315):. PubMed ID: 27884981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Transient and Partial Cell Reprogramming to Pluripotency as a Therapeutic Tool for Neurodegenerative Diseases.
    Tamanini S; Comi GP; Corti S
    Mol Neurobiol; 2018 Aug; 55(8):6850-6862. PubMed ID: 29353456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sox2 expression effects on direct reprogramming efficiency as determined by alternative somatic cell fate.
    Yamaguchi S; Hirano K; Nagata S; Tada T
    Stem Cell Res; 2011 Mar; 6(2):177-86. PubMed ID: 21130722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo partial reprogramming of myofibers promotes muscle regeneration by remodeling the stem cell niche.
    Wang C; Rabadan Ros R; Martinez-Redondo P; Ma Z; Shi L; Xue Y; Guillen-Guillen I; Huang L; Hishida T; Liao HK; Nuñez Delicado E; Rodriguez Esteban C; Guillen-Garcia P; Reddy P; Izpisua Belmonte JC
    Nat Commun; 2021 May; 12(1):3094. PubMed ID: 34035273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay of chromatin and transcription factors during cell fate transitions in development and reprogramming.
    Peñalosa-Ruiz G; Bright AR; Mulder KW; Veenstra GJC
    Biochim Biophys Acta Gene Regul Mech; 2019 Sep; 1862(9):194407. PubMed ID: 31356991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of apoptosis gene loci by reprogramming factors leads to selective eradication of leukemia cells.
    Wang Y; Lu T; Sun G; Zheng Y; Yang S; Zhang H; Hao S; Liu Y; Ma S; Zhang H; Ru Y; Gao S; Yen K; Cheng H; Cheng T
    Nat Commun; 2019 Dec; 10(1):5594. PubMed ID: 31811153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression of OCT4, SOX2, KLF4 and MYC (OSKM) induced pluripotent stem cells: identification for potential mechanisms.
    Cai Y; Dai X; Zhang Q; Dai Z
    Diagn Pathol; 2015 Apr; 10():35. PubMed ID: 25907774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα.
    Bueno C; Sardina JL; Di Stefano B; Romero-Moya D; Muñoz-López A; Ariza L; Chillón MC; Balanzategui A; Castaño J; Herreros A; Fraga MF; Fernández A; Granada I; Quintana-Bustamante O; Segovia JC; Nishimura K; Ohtaka M; Nakanishi M; Graf T; Menendez P
    Leukemia; 2016 Mar; 30(3):674-82. PubMed ID: 26500142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of Fibrosis and Scar Formation by Partial Reprogramming In Vivo.
    Doeser MC; Schöler HR; Wu G
    Stem Cells; 2018 Aug; 36(8):1216-1225. PubMed ID: 29761584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible reprogramming of cardiomyocytes to a fetal state drives heart regeneration in mice.
    Chen Y; Lüttmann FF; Schoger E; Schöler HR; Zelarayán LC; Kim KP; Haigh JJ; Kim J; Braun T
    Science; 2021 Sep; 373(6562):1537-1540. PubMed ID: 34554778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of Induced Progenitor-like Cells from Mature Epithelial Cells Using Interrupted Reprogramming.
    Guo L; Karoubi G; Duchesneau P; Shutova MV; Sung HK; Tonge P; Bear C; Rogers I; Nagy A; Waddell TK
    Stem Cell Reports; 2017 Dec; 9(6):1780-1795. PubMed ID: 29198829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells.
    Martinez-Fernandez A; Nelson TJ; Ikeda Y; Terzic A
    J Cardiovasc Transl Res; 2010 Feb; 3(1):13-23. PubMed ID: 20221419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging methods for preparing iPS cells.
    Miyazaki S; Yamamoto H; Miyoshi N; Takahashi H; Suzuki Y; Haraguchi N; Ishii H; Doki Y; Mori M
    Jpn J Clin Oncol; 2012 Sep; 42(9):773-9. PubMed ID: 22826352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cells act as an extrinsic barrier for in vivo reprogramming.
    Melendez E; Chondronasiou D; Mosteiro L; Martínez de Villarreal J; Fernández-Alfara M; Lynch CJ; Grimm D; Real FX; Alcamí J; Climent N; Pietrocola F; Serrano M
    Development; 2022 Apr; 149(8):. PubMed ID: 35420133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.